Friday, 19 Oct 2018

Biologic/Novel Rx

Datesort ascending Type Title Save
24 Jul 2017 Social Samsung Bioepis launches U.S. sales of Remicade biosmiliar- Renflexis
24 Jul 2017 News Rheumatologists and Patients Concerns over Biosimilars - RheumNow “Live Vote” Results
20 Jul 2017 Social 7 pts w/ Active Refractory Takayasu arteritis Tx w/ RTX w/ mixed results - 3 achieved remission but 4 failed to resp
13 Jun 2017 News Supreme Court Decision Favors Earlier Biosimilar Adoption
07 Jun 2017 News Upadacitinib Effective in Rheumatoid Arthritis
05 Jun 2017 News Biosimilar Reports – May 2017
25 May 2017 Social RT @RWCSmtg: NOR-SWITCH trial suggests Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13 #psoriasis…
24 May 2017 News Anti-IL-5 Success in Eosinophilic Granulomatosis with Polyangiitis
23 May 2017 Social Kevzara-the 2nd IL-6 inhibitor approved for use in RA; priced at $39K, 30% below competition
23 May 2017 Social FDA approves Actemra as1st approved drug to treat Giant Cell Arteritis. See RheumNow report.
23 May 2017 News Actemra - First FDA Approved Drug for Giant Cell Arteritis
22 May 2017 Social @naseema22537544 @DrSimply The new updated PI says its to be given with a tapering course of steroids.
18 May 2017 Social RT @DrPetryna: @RheumNow could ustekinumab potentially be used in treatment of refractory GCA? Evidence suggests it might…
15 May 2017 Social In #Crohns disease Tofacitinib fails to maintain remission in randomized W/D, results of 2 Placebo RCT.
12 May 2017 Social Uptacitinib (Abbvie Jak 1 inhibitor) shows efficacy in Crohns dz (CELESTE RCTl) w/ remission rates at 6 &24 mg bid
10 May 2017 Social Responses to Orencia may be dependent on baseline memory B cells (CD38+ CD27+)
07 May 2017 Social FDA has accepted Sanofi/Regenerons resubmitted BLA for Sarilumab (IL-6 inhib) for RA w/ PFUFA action date 5/22/17
05 May 2017 Social Japan Study shows 8mg IV Actemra can be escalated to q3 wks IV or reduced to q5 wks IV according to q4wk response
04 May 2017 News Tofacitinib Effective in Ulcerative Colitis
04 May 2017 Social Pfizer submitted tofacitinib NDA to FDA for psoriatic arthritis. FDA prev denied the NDA for psoriasis w/ CR letter.